Formycon Overview

  • Founded

  • 1999

Founded
  • Status

  • Public

  • Employees

  • 137

Employees
  • Stock Symbol

  • FYB

Stock Symbol
  • Investments

  • 4

  • Share Price

  • $82.25

  • (As of Friday Closing)

Formycon General Information

Description

Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID 19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.

Contact Information

Website
www.formycon.com
Formerly Known As
Nanohale AG
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
ETR
Primary Office
  • Fraunhoferstraße 15
  • Planegg
  • 82152 Martinsried
  • Germany
+49 089 000000000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Formycon Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$82.25 $84.65 $65.63 - $100.27 $1.24B 15.1M 14.3K $2.75

Formycon Financials Summary

In Thousands,
USD 		TTM 31-Dec-2022 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 1,379,202 1,379,202 699,120 694,314
Revenue 44,681 44,681 43,287 39,094
EBITDA 40,249 40,249 (14,847) (6,499)
Net Income 37,842 37,842 (15,713) (7,670)
Total Assets 550,662 550,662 76,246 92,983
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Formycon Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Formycon‘s full profile, request access.

Request a free trial

Formycon Patents

  • 52

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 5

    Granted

  • 4

    Pending

  • 000

    Expiring in next 12 mo

Formycon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021367988-A1 Ace2 fusion proteins and uses thereof Pending 29-Oct-2020 00000000
CA-3193930-A1 Ace2 fusion proteins and uses thereof Pending 29-Oct-2020 00000000
CA-3174236-A1 Ace2-fc fusion proteins and uses thereof Pending 22-May-2020 000000000
EP-4139002-A2 Ace2-fc fusion proteins and uses thereof Pending 22-May-2020 000000000
AU-2021275499-A1 Ace2-fc fusion proteins and uses thereof Pending 22-May-2020 C12Y304/17023
To view Formycon’s complete patent history, request access »

Formycon Executive Team (6)

Name Title Board Seat Contact Info
Stefan Glombitza Ph.D Chief Executive Officer
Nicolas Combé Ph.D Chief Financial Officer
Andreas Seidl Chief Scientific Officer
Nicola Mikulcik Chief Business Officer
Enno Spillner Board (CFO)
You’re viewing 5 of 6 executive team members. Get the full list »

Formycon Board Members (1)

Name Representing Role Since
Enno Spillner Self Board (CFO) 000 0000
To view Formycon’s complete board members history, request access »

Formycon Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Formycon Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Formycon‘s full profile, request access.

Request a free trial

Formycon Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 (000) 10-May-2022 0000000000 00000 Pharmaceuticals 0000000 0
000 000 01-May-2022 0000000000 00000 Biotechnology 0000000 0
000 000 22-Dec-2017 00000 0000 Biotechnology
Scil Technology (R&D & Service Units) 31-Dec-2011 Merger/Acquisition Discovery Tools (Healthcare)
To view Formycon’s complete investments and acquisitions history, request access »

Formycon ESG

Risk Overview

Risk Rating

Updated December, 31, 2022

26.05 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,233

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 866

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 382

Rank

00.00

Percentile

To view Formycon’s complete esg history, request access »